- Whoop and Kinomatic have launched a joint recovery pilot program called Restore targeting the post-operative care gap in orthopedic surgery: after a knee or hip replacement, patients typically see their surgeon at two weeks and attend physical therapy a few times a week, with minimal clinical visibility into what is happening in between — the Restore program aims to close that gap by streaming Whoop biometric data (heart rate variability, sleep quality, strain, and recovery scores) directly to surgeons and patient navigators throughout the 12-week recovery window, enabling clinicians to identify patients who are struggling or at risk before problems escalate to the next scheduled appointment; the pilot will enroll more than 100 patients across three California orthopedic clinics, with Kinomatic providing a concierge care coordination service layered on top of the wearable data stream.
- The primary clinical goals of the Restore pilot are outcome improvement and opioid reduction — two of the most significant cost and quality problems in orthopedic surgery recovery; outcomes will be measured by range of motion in knee and hip flexion at two weeks post-surgery with a follow-up assessment at one year, providing both near-term and long-term data on whether continuous biometric monitoring translates into meaningful clinical improvements; opioid reduction is the second key endpoint, reflecting the well-documented risk that orthopedic surgery patients can become dependent on post-operative opioid prescriptions when pain management is not actively monitored and adjusted — the hypothesis is that more frequent data-driven touchpoints allow earlier intervention that can reduce both opioid dosing and duration.
- The Whoop-Kinomatic partnership is part of a broader industry shift toward biometrics in clinical care that is being enabled by a more permissive FDA regulatory posture: the FDA earlier in 2026 loosened its oversight of certain software features in wearable devices, allowing blood pressure measurements to fall under a wellness exemption rather than requiring device clearance, which substantially reduces the regulatory burden for wearable companies seeking clinical partnerships; orthopedic device manufacturers are moving in parallel — Zimmer Biomet has incorporated sensors into certain knee implants and paired them with a care management platform, creating a “smart implant” ecosystem that generates in-body data on joint performance post-surgery; the convergence of FDA flexibility and manufacturer investment is creating infrastructure for wearable biometrics to move from consumer fitness into clinical care at scale.
- For Whoop specifically, the Restore pilot represents a strategic pivot toward clinical validation that could open significant new market opportunities: Whoop has historically sold direct-to-consumer fitness trackers at a premium price point, building a loyal base among athletes and health-conscious consumers; a clinically validated role in post-surgical recovery would give Whoop a pathway into hospital and health system procurement, potentially enabling it to be prescribed or recommended by orthopedic surgeons — a very different and much larger commercial channel than direct-to-consumer; the FDA dropped a warning letter it had issued to Whoop over its blood pressure feature earlier in 2026, removing a potential regulatory overhang and signaling a more constructive relationship between Whoop and regulators as it pursues clinical applications.
What Happened?
Whoop and Kinomatic announced a 12-week pilot program called Restore to test biometric-guided recovery after knee and hip replacement surgery. The pilot will enroll more than 100 patients at three California orthopedic clinics and will stream Whoop wearable data — heart rate variability, sleep, strain, and recovery — to surgeons and patient navigators between visits. The primary endpoints are improved range of motion and reduced opioid use, with measurements at two weeks and one year post-surgery.
Why It Matters?
Joint replacement is one of the most common and costly surgical procedures in the US, with more than one million knee and hip replacements performed annually. The post-operative recovery period is characterized by limited clinical visibility — patients are largely on their own between scheduled appointments — and meaningful rates of opioid dependence and suboptimal functional outcomes. If the Restore pilot demonstrates that continuous biometric monitoring can improve range of motion and reduce opioid prescribing, it would provide the clinical evidence base needed for health systems to procure wearables as part of the standard of care, and for payers to reimburse them — the two barriers that have historically limited wearables’ penetration into clinical pathways despite strong consumer adoption.
What’s Next?
Watch for the Restore pilot’s two-week outcome data, which will be the first clinical signal on whether the Whoop-Kinomatic model is generating meaningful results; watch whether Whoop announces expansion of the pilot to additional clinics or health systems if early data is positive, which would indicate commercial traction; watch the reimbursement landscape — a survey published earlier this month found that workflow integration and reimbursement barriers remain the primary obstacles to physician use of wearable data, and any payer moves to cover wearable-assisted recovery programs would be a significant catalyst for the sector; and watch Zimmer Biomet’s smart implant data releases, as clinical evidence from embedded sensors in knee implants would complement and accelerate the case for wearable monitoring in orthopedic recovery.
Source: Healthcare Dive
